Memorial Sloan Kettering Cancer Center: Prostatic Neoplasms trials

The registry lists 129 Prostatic Neoplasms studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 15 are open to participants now and 24 have results posted.

Phase 1 38Phase 2 52Phase 3 8No phase 43(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prostate Biomarker StudyCompletedNCT00574899
• Communication and Intimacy-Enhancing Therapy for Men With Early Stage Prostate Cancer and Their PartnersStatus unknownNCT00503646Not applicable
• Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their PartnersCompletedNCT00483678Not applicable
• Psychostimulants for Fatigue in Prostate CancerCompletedNCT00138138Phase 2
• Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the ProstateCompletedNCT00081172Phase 2
• Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate CancerCompletedNCT00067015Phase 3
• Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate CancerCompletedNCT00059943Phase 2
• Vaccine Therapy Plus QS21 in Treating Patients With Prostate CancerCompletedNCT00036933Phase 1
• Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate CancerCompletedNCT00025194Phase 1/2
• Monoclonal Antibody Therapy in Treating Patients With Prostate CancerCompletedNCT00024232Phase 2
• CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation TherapyCompletedNCT00020891Phase 2
• Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate CancerCompletedNCT00016146Phase 1
• Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate CancerCompletedNCT00014352Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Prostate CancerCompletedNCT00006380Phase 1
• Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone TherapyCompletedNCT00006044Phase 1
• Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerCompletedNCT00006019Phase 2
• Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous TherapyCompletedNCT00005634Phase 1
• Vaccine Therapy Plus QS21 in Treating Patients With Prostate CancerCompletedNCT00005632Phase 1
• Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate CancerCompletedNCT00004929Phase 1
• Calcitriol and Zoledronate in Treating Patients With Progressive Prostate CancerCompletedNCT00004928Phase 1
• Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic CancerCompletedNCT00004065Phase 1
• Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate CancerCompletedNCT00003819Phase 1
• Trastuzumab in Treating Patients With Prostate CancerCompletedNCT00003740Phase 2
• Combination Chemotherapy in Treating Patients With Advanced Prostate CancerCompletedNCT00003394Phase 1/2
• Diet and PSA Levels in Patients With Prostate CancerCompletedNCT00003367Phase 3
• Computer Planned Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00003104Phase 2
• Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1/2
• Biological Therapy in Treating Patients With Prostate CancerCompletedNCT00002637Phase 1/2
• Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00002480Phase 1